Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. (Q54300242)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

13

object named as

Eric Winer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1

object named as

Sara Tolaney

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Howard Burris

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Elaina Gartner

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Ingrid A Mayer

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Matthew Maurer

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Agustin A Garcia

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Frank Campana

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Bin Wu

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Yi Xu

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Jason Jiang

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Ian Krop

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

language of work or name

0 references

publication date

24 December 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

149

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

151-161

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

https://scigraph.springernature.com/pub.10.1007/s10549-014-3248-4

0 references

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

BEAMing up for detection and quantification of rare sequence variants.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3248-4

21 January 2018

Identifiers

10.1007/S10549-014-3248-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25537644%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54300242&oldid=1872253719"